Taipei, Taiwan, February 23, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its Zhongli facility, part of Bora’s CDMO network, has been officially approved and registered as a bonded factory by Taipei Customs in Taiwan. The unveiling ceremony was jointly hosted by Chih-Jen Hsu, Deputy Director of Taipei Customs, Alice Wang, Chief Financial Officer of Bora, and Tom Chang, Senior Vice President of Bora.
Tom Chang, Senior Vice President of Bora, noted that Bora’s CDMO business is primarily export-oriented and operates under stringent requirements for on-time and in-full delivery. “As the order backlog at the Zhongli facility continues to grow, the bonded manufacturing status shared by both the Zhongli and Zhunan sites will enable more flexible, cross-site coordination in container loading and shipment scheduling. This will help minimize logistics bottlenecks and waiting times, enhance overall supply chain responsiveness, and further strengthen international pharmaceutical partners’ confidence in Bora’s integrated Taiwan – North America contract manufacturing network.”
Taipei Customs stated that bonded factories benefit from expedited customs clearance and exemptions from duties and taxes on imported materials processed for export, helping to lower operating costs and enhance international competitiveness. Taipei Customs will continue to uphold its service-oriented approach by providing a more efficient and high-quality customs clearance environment, supporting bonded manufacturers in capturing additional business opportunities and expanding export growth.